Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.020 AlteredExpression group BEFREE Analyses of the Notch target genes HES5 and MASH1 in MEC tumors with and without the WAMTP1-MAML2 fusion revealed upregulation of HES5 and downregulation of MASH1 in fusion positive MECs compared to normal salivary gland tissue and MECs lacking the fusion. 14720503 2004
CUI: C0206694
Disease: Mucoepidermoid Carcinoma
Mucoepidermoid Carcinoma 		0.020 Biomarker disease BEFREE Analyses of the Notch target genes HES5 and MASH1 in MEC tumors with and without the WAMTP1-MAML2 fusion revealed upregulation of HES5 and downregulation of MASH1 in fusion positive MECs compared to normal salivary gland tissue and MECs lacking the fusion. 14720503 2004
CUI: C0206694
Disease: Mucoepidermoid Carcinoma
Mucoepidermoid Carcinoma 		0.020 Biomarker disease BEFREE Analyses of potential downstream targets of the fusion revealed differential expression of the cAMP/CREB (FLT1 and NR4A2) and Notch (HES1 and HES5) target genes in fusion-positive and fusion-negative MECs. 16444749 2006
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.020 AlteredExpression disease BEFREE However, in nonserotonergic cells that express 5-HT1A receptors (septal SN48, neuroblastoma SKN-SH, and neuroblastoma/glioma NG108-15 cells), Deaf-1 enhanced 5-HT1A promoter activity at the C(-1019)-allele but not the G-allele, whereas Hes5 repressed in all cell types. 16467535 2006
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.020 AlteredExpression disease BEFREE However, in nonserotonergic cells that express 5-HT1A receptors (septal SN48, neuroblastoma SKN-SH, and neuroblastoma/glioma NG108-15 cells), Deaf-1 enhanced 5-HT1A promoter activity at the C(-1019)-allele but not the G-allele, whereas Hes5 repressed in all cell types. 16467535 2006
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.020 AlteredExpression disease BEFREE However, in nonserotonergic cells that express 5-HT1A receptors (septal SN48, neuroblastoma SKN-SH, and neuroblastoma/glioma NG108-15 cells), Deaf-1 enhanced 5-HT1A promoter activity at the C(-1019)-allele but not the G-allele, whereas Hes5 repressed in all cell types. 16467535 2006
CUI: C0017638
Disease: Glioma
Glioma 		0.010 AlteredExpression disease BEFREE However, in nonserotonergic cells that express 5-HT1A receptors (septal SN48, neuroblastoma SKN-SH, and neuroblastoma/glioma NG108-15 cells), Deaf-1 enhanced 5-HT1A promoter activity at the C(-1019)-allele but not the G-allele, whereas Hes5 repressed in all cell types. 16467535 2006
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms 		0.010 AlteredExpression group BEFREE In this study, we show that NOTCH signaling, as measured by the gamma-secretase cleavage product N(IC)-1, is active in both normal human and lung tumor samples; however, downstream NOTCH readouts (i.e., HES-1 and HES-5) are elevated in lung tumors. 17804701 2007
CUI: C0004114
Disease: Astrocytoma
Astrocytoma 		0.010 AlteredExpression disease BEFREE Using RT-PCR, we found that most human astrogliomas of different grades expressed moderate to high level of Notch receptors and ligands. mRNA of Hes5 but not Hes1, both of which are major downstream molecules of the Notch pathway, was also detected. 17849174 2008
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis 		0.010 AlteredExpression disease LHGDN Notch1, Jagged1, and HES5 are abundantly expressed in osteoarthritis. 18354251 2008
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis 		0.010 AlteredExpression disease BEFREE Notch1, Jagged1, and HES5 are abundantly expressed in osteoarthritis. 18354251 2008
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms 		0.300 Biomarker group CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C0153633
Disease: Malignant neoplasm of brain
Malignant neoplasm of brain 		0.300 Biomarker disease CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C0496899
Disease: Benign neoplasm of brain, unspecified
Benign neoplasm of brain, unspecified 		0.300 Biomarker disease CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C0750974
Disease: Brain Tumor, Primary
Brain Tumor, Primary 		0.300 Biomarker disease CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C0750977
Disease: Recurrent Brain Neoplasm
Recurrent Brain Neoplasm 		0.300 Biomarker disease CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C0750979
Disease: Primary malignant neoplasm of brain
Primary malignant neoplasm of brain 		0.300 Biomarker disease CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C1527390
Disease: Neoplasms, Intracranial
Neoplasms, Intracranial 		0.300 Biomarker group CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C0024809
Disease: Marijuana Abuse
Marijuana Abuse 		0.010 AlteredExpression disease BEFREE Hairy and enhancer of split 1 (Hes1) and Hes5 are target genes for the mammalian Notch pathway, which are highly expressed in epithelia in the process of embryogenesis or in neural stem cells, inhibit cell differentiation via the Notch-Hes-Hash signaling, and promote the survival of stem cells. 21495212 2010
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.010 Biomarker phenotype BEFREE Either Hes1 or Hes5 overactivation is likely to affect cell differentiation, thereby resulting in carcinogenesis. 21495212 2010
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.020 PosttranslationalModification disease BEFREE The HES2 and HES5 gene promoters were found to be heavily methylated in most neuroblastoma lines, and HES gene expression could be induced through treatment with decitabine. 21744479 2012
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.020 PosttranslationalModification disease BEFREE The HES2 and HES5 gene promoters were found to be heavily methylated in most neuroblastoma lines, and HES gene expression could be induced through treatment with decitabine. 21744479 2012
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.020 PosttranslationalModification disease BEFREE The HES2 and HES5 gene promoters were found to be heavily methylated in most neuroblastoma lines, and HES gene expression could be induced through treatment with decitabine. 21744479 2012
CUI: C0027765
Disease: nervous system disorder
nervous system disorder 		0.300 Biomarker group CTD_human A 3-dimensional human embryonic stem cell (hESC)-derived model to detect developmental neurotoxicity of nanoparticles. 23203475 2013
CUI: C1292769
Disease: Precursor B-cell lymphoblastic leukemia
Precursor B-cell lymphoblastic leukemia 		0.010 PosttranslationalModification disease BEFREE 5-aza-2'-deoxycytidine treatment restored Hes5 expression and decreased promoter hypermethylation in most leukemia cell lines and primary B-ALL samples. 23637910 2013